38 min
EPISODE #94 Cannabis and the Pharmaceutical Drug Development Process with Gavin Sathianathan & Neil Mahapatra from Oxford Cannabinoid Technologies The Cannabis Conversation | Medical Cannabis | CBD | Hemp
-
- Business
On this week’s show we’re joined by Gavin Sathianathan & Neil Mahapatra from Oxford Cannabinoid Technologies (OCT) - UK biopharmaceutical company focused on cannabinoid drug development and world class scientific research.
We explore the pharmaceutical drug development process, including how clinical trials work, the capital required to make one a success, and how big pharma fit into the value chain.
→ View full show notes and summary here: https://www.canverse.global/shownotes/episode-94-cannabis-and-the-pharmaceutical-drug-development-process-with-gavin-sathianathan-amp-neil-mahapatra-from-oxford-cannabinoid-technologies
About OCT
OCT was established in 2017 by UK private equity firm Kingsley Capital Partners, as a biopharmaceutical company focused on cannabinoid drug development. The company’s vision is to become the global leader in developing prescription medicines that target the endocannabinoid system and address significant unmet medical needs. To achieve its aim, OCT uses a drug development strategy that includes proprietary cannabinoid derivatives, natural phytocannabinoids, and other drug candidates. Since inception, the company has grown significantly, expanded its research and library of cannabinoid derivatives, and completed two rounds of investment.
About Gavin
Gavin Sathianathan is a serial entrepreneur and acknowledged leader in the cannabis industry, and serves as CEO of Alta Flora, a tech company focused on improving quality of life through understanding data on symptoms and medications. Gavin started his cannabis industry experience in 2014, initially in the US before establishing Alta Flora in Europe. In addition to his role as CEO of Alta Flora, Gavin serves on the board of Oxford Cannabinoid Technologies. Gavin has a degree in Chemical Engineering from Imperial College and an MBA from Harvard Business School.
About Neil
Neil is a co-founder and Managing Partner of Kingsley Capital Partners and is responsible for sourcing and managing investments across TMT and Life Sciences. Through Kingsley, he founded Oxford Cannabinoid Technologies and also Equinox International Holdings, which holds a licence to cultivate medical cannabis in the UK and retails CBD under the Mr NICE brand. Neil began his career in investment banking at Morgan Stanley in London before moving to J. Rothschild Capital Management, where he led private investments for Lord Rothschild’s family office and RIT Capital Partners plc. Neil holds a degree in Biological Sciences from the University of Oxford, where he was also President of the Oxford Union, and an MBA from the Harvard Business School.
Resources
Follow Neil on LinkedIn: https://www.linkedin.com/in/neil-mahapatra-2818141/
Follow Gavin on LinkedIn: https://www.linkedin.com/in/gavinsathianathan/
Oxford Cannabinoid Technologies Website: https://www.oxcantech.com/
On this week’s show we’re joined by Gavin Sathianathan & Neil Mahapatra from Oxford Cannabinoid Technologies (OCT) - UK biopharmaceutical company focused on cannabinoid drug development and world class scientific research.
We explore the pharmaceutical drug development process, including how clinical trials work, the capital required to make one a success, and how big pharma fit into the value chain.
→ View full show notes and summary here: https://www.canverse.global/shownotes/episode-94-cannabis-and-the-pharmaceutical-drug-development-process-with-gavin-sathianathan-amp-neil-mahapatra-from-oxford-cannabinoid-technologies
About OCT
OCT was established in 2017 by UK private equity firm Kingsley Capital Partners, as a biopharmaceutical company focused on cannabinoid drug development. The company’s vision is to become the global leader in developing prescription medicines that target the endocannabinoid system and address significant unmet medical needs. To achieve its aim, OCT uses a drug development strategy that includes proprietary cannabinoid derivatives, natural phytocannabinoids, and other drug candidates. Since inception, the company has grown significantly, expanded its research and library of cannabinoid derivatives, and completed two rounds of investment.
About Gavin
Gavin Sathianathan is a serial entrepreneur and acknowledged leader in the cannabis industry, and serves as CEO of Alta Flora, a tech company focused on improving quality of life through understanding data on symptoms and medications. Gavin started his cannabis industry experience in 2014, initially in the US before establishing Alta Flora in Europe. In addition to his role as CEO of Alta Flora, Gavin serves on the board of Oxford Cannabinoid Technologies. Gavin has a degree in Chemical Engineering from Imperial College and an MBA from Harvard Business School.
About Neil
Neil is a co-founder and Managing Partner of Kingsley Capital Partners and is responsible for sourcing and managing investments across TMT and Life Sciences. Through Kingsley, he founded Oxford Cannabinoid Technologies and also Equinox International Holdings, which holds a licence to cultivate medical cannabis in the UK and retails CBD under the Mr NICE brand. Neil began his career in investment banking at Morgan Stanley in London before moving to J. Rothschild Capital Management, where he led private investments for Lord Rothschild’s family office and RIT Capital Partners plc. Neil holds a degree in Biological Sciences from the University of Oxford, where he was also President of the Oxford Union, and an MBA from the Harvard Business School.
Resources
Follow Neil on LinkedIn: https://www.linkedin.com/in/neil-mahapatra-2818141/
Follow Gavin on LinkedIn: https://www.linkedin.com/in/gavinsathianathan/
Oxford Cannabinoid Technologies Website: https://www.oxcantech.com/
38 min